Accès gratuit
Med Sci (Paris)
Volume 23, Numéro 12, Décembre 2007
Page(s) 1115 - 1124
Section M/S revues
Publié en ligne 15 décembre 2007
  1. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988; 80 : 200–4.
  2. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3 : 55–63.
  3. Christofori G. New signals from the invasive front. Nature 2006; 441 : 444–50.
  4. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8 : 341–52.
  5. Rinker-Schaeffer CW, O’Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 2006; 12 : 3882–9.
  6. Wallet V, Mutzel R, Troll H, et al. Dictyostelium nucleoside diphosphate kinase highly homologous to Nm23 and Awd proteins involved in mammalian tumor metastasis and Drosophila development. J Natl Cancer Inst 1990; 82 : 1199–202.
  7. Lacombe ML, Milon L, Munier A, et al. The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr 2000; 32 : 247–58.
  8. Boissan M, Lacombe ML. Nm23/NDP kinases in hepatocellular carcinoma. J Bioenerg Biomembr 2006; 38 : 169–75.
  9. Boissan M, Wendum D, Arnaud-Dabernat S, et al. Increased lung metastasis in transgenic NM23-Null/SV40 mice with hepatocellular carcinoma. J Natl Cancer Inst 2005; 97 : 836–45.
  10. Otsuki Y, Tanaka M, Yoshii S, et al. Tumor metastasis suppressor nm23H1 regulates Rac1 GTPase by interaction with Tiam1. Proc Natl Acad Sci USA 2001; 98 : 4385–90.
  11. Salerno M, Palmieri D, Bouadis A, et al. Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells. Mol Cell Biol 2005; 25 : 1379–88.
  12. Dammai V, Adryan B, Lavenburg KR, Hsu T. Drosophila awd, the homolog of human nm23, regulates FGF receptor levels and functions synergistically with shi/dynamin during tracheal development. Genes Dev 2003; 17 : 2812–24.
  13. Fournier HN, Dupe-Manet S, Bouvard D, et al. Integrin cytoplasmic domain-associated protein 1alpha (ICAP-1alpha) interacts directly with the metastasis suppressor nm23-H2, and both proteins are targeted to newly formed cell adhesion sites upon integrin engagement. J Biol Chem 2002; 277 : 20895–902.
  14. Horak CE, Lee JH, Elkahloun A, et al. NM23-H1 suppresses tumor cell motility by downregulating the LPA receptor. Cancer Res 2007; 67 : 7238–46.
  15. Goswami S, Yoon J, Abramczyk B, et al. Molecular and functional interactions between Escherichia coli nucleoside-diphosphate kinase and the uracil-DNA glycosylase Ung. J Biol Chem 2006; 281 : 32131–9.
  16. Fan Z, Beresford PJ, Oh DY, et al. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003; 112 : 659–72.
  17. Gildea JJ, Seraj MJ, Oxford G, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002; 62 : 6418–23.
  18. Gelman IH, Gao L. SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via RhoA- and Cdc42-dependent pathways. Mol Cancer Res 2006; 4 : 151–8.
  19. Su B, Zheng Q, Vaughan MM, et al. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. Cancer Res 2006; 66 : 5599–607.
  20. Nash KT, Phadke PA, Navenot JM, et al. Requirement of KISS1 secretion for multiple organ metastasis suppression and maintenance of tumor dormancy. J Natl Cancer Inst 2007; 99 : 309–21.
  21. Yan C, Wang H, Boyd DD. KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of Ikappa Balpha -induced block of p65/p50 nuclear translocation. J Biol Chem 2001; 276 : 1164–72.
  22. Goldberg SF, Miele ME, Hatta N, et al. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res 2003; 63 : 432–40.
  23. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003; 63 : 1684–95.
  24. Vander Griend DJ, Kocherginsky M, Hickson JA, et al. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 2005; 65 : 10984–91.
  25. Hickson JA, Huo D, Vander Griend DJ, et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 2006; 66 : 2264–70.
  26. Motwani M, Sirotnak FM, She Y, et al. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 2002; 62 : 3950–5.
  27. Schuierer MM, Bataille F, Weiss TS, et al. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 2006; 16 : 451–6.
  28. Odintsova E, Sugiura T, Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol 2000; 10 : 1009–12.
  29. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 2006; 25 : 2367–78.
  30. Bandyopadhyay S, Zhan R, Chaudhuri A, et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 2006; 12 : 933–8.
  31. Cicek M, Fukuyama R, Welch DR, et al. Breast cancer metastasis suppressor 1 inhibits gene expression by targeting nuclear factor-kappaB activity. Cancer Res 2005; 65 : 3586–95.
  32. Samant RS, Clark DW, Fillmore RA, et al. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 2007; 6 : 6.
  33. Saunders MM, Seraj MJ, Li Z, et al. Breast cancer metastatic potential correlates with a breakdown in homospecific and heterospecific gap junctional intercellular communication. Cancer Res 2001; 61 : 1765–7.
  34. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446 : 690–4.
  35. Hailat N, Keim DR, Melhem RF, et al. High levels of p19/nm23 protein in neuroblastoma are associated with advanced stage disease and with N-myc gene amplification. J Clin Invest 1991; 88 : 341–5.
  36. Cunningham SC, Gallmeier E, Hucl T, et al. Targeted deletion of MKK4 in cancer cells: a detrimental phenotype manifests as decreased experimental metastasis and suggests a counterweight to the evolution of tumor-suppressor loss. Cancer Res 2006; 66 : 5560–4.
  37. Sheth SS, Bodnar JS, Ghazalpour A, et al. Hepatocellular carcinoma in Txnip-deficient mice. Oncogene 2006; 25 : 3528–36.
  38. Palmieri D, Halverson DO, Ouatas T, et al. Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 2005; 97 : 632–42.
  39. Titus B, Frierson HF Jr, Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005; 65 : 7320–7.
  40. Li J, Zhou J, Chen G, et al. Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. Cancer Gene Ther 2006; 13 : 266–72.
  41. Takeda T, Hattori N, Tokuhara T, et al. Adenoviral transduction of MRP-1/CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res 2007; 67 : 1744–9.
  42. Chabas D. L’ostéopontine, une molécule aux multiples facettes. Med Sci (Paris) 2005; 21 : 832–8.
  43. Nasarre P, Constantin B, Drabkin HA, Roche J. Sémaphorines et cancer : état des lieux. Med Sci (Paris) 2005; 21 : 641–7.
  44. Desjardins SF, Berchiche YA, Haddad E, Heveker N. CXCR4, un récepteur de chimiokine aux multiples talents. Med Sci (Paris) 2007; 23 : 980–4.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.